Loading...
XLONDXRX
Market cap143mUSD
Jan 03, Last price  
136.50GBP
1D
0.37%
1Q
2.63%
IPO
40.00%
Name

Diaceutics PLC

Chart & Performance

D1W1MN
XLON:DXRX chart
P/E
P/S
486.55
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
3.89%
Rev. gr., 5y
17.97%
Revenues
24m
+21.51%
1,397,5744,588,6987,370,60810,373,18013,442,12112,696,00013,943,00019,504,00023,699,000
Net income
-2m
L
-103,488747,139663,193632,307398,000263,000561,000724,000-1,746,000
CFO
1m
-74.53%
0674,0141,534,168-954,038-627,054253,000570,0005,148,0001,311,000
Earnings
May 19, 2025

Profile

Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics. The company also provides DXRX patient journey that enables pharma customers to complete a longitudinal analysis of biomarker testing journeys of individual patients, which identifies opportunities for earlier testing and treatment; DXRX lab benchmarking that enables laboratories to gain competitive edge and compare key criteria to others in the industry providing metrics, such as disease, testing and methodology, market share, turnaround time, and laboratory leadership in these areas; DXRX test reimbursement, which enables pharma customers to engage with laboratories to fund the introduction of novel companion diagnostics, as well as reducing the lag time in test adoption; and DXRX test signal that delivers a real-time alert of a testing event, which allows pharma customers to identify therapeutically actionable patients in the previous weeks. In addition, it offers diagnostic landscape, planning, implementation, and tracking services; and consulting services for precision medicine diagnostics. Further, the company provides test standardization, test quality assessment, test report optimization, laboratory tech support, test access and reimbursement, laboratory training, and educational resources services. Diaceutics PLC was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.
IPO date
Mar 21, 2019
Employees
151
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
23,699
21.51%
19,504
39.88%
Cost of revenue
26,777
19,173
Unusual Expense (Income)
NOPBT
(3,078)
331
NOPBT Margin
1.70%
Operating Taxes
(692)
(246)
Tax Rate
NOPAT
(2,386)
577
Net income
(1,746)
-341.16%
724
29.06%
Dividends
Dividend yield
Proceeds from repurchase of equity
(49)
31
BB yield
0.07%
-0.05%
Debt
Debt current
146
124
Long-term debt
2,264
2,410
Deferred revenue
Other long-term liabilities
88
79
Net debt
(14,257)
(34,443)
Cash flow
Cash from operating activities
1,311
5,148
CAPEX
(125)
(4,870)
Cash from investing activities
(4,209)
(4,870)
Cash from financing activities
(239)
(132)
FCF
5,234
1,216
Balance
Cash
16,667
19,841
Long term investments
17,136
Excess cash
15,482
36,002
Stockholders' equity
4,212
5,651
Invested Capital
37,867
37,848
ROIC
1.52%
ROCE
0.75%
EV
Common stock shares outstanding
84,227
86,090
Price
0.87
15.23%
0.76
-25.98%
Market cap
73,277
12.74%
64,998
-24.98%
EV
59,020
30,555
EBITDA
1,695
3,339
EV/EBITDA
34.82
9.15
Interest
66
122
Interest/NOPBT
36.86%